| I. Confirmation of DAF-12/VDRtarget genes in previous publications. |
| Human STAM/C. elegans gene name: C34G6.7, VDR/daf-12,TNFAIP3/Y50C1A.1, FCRL3/ttn-1, FOXP3/fkh-7, RASGRP3/rgef-1, Cyp24a/cyp-44a1, CYP-0a1/cyp-13b1, PRKCQ/T13H5.8, CD93/F56H11.1,NFkB/lit-1, HDAC6/F41H10.6, CCNC/cic-1, JMJD3/D008.1, JMJD2, HDAC/hda-2, PTPN0 /Y41D4A.5, IGFBP5/C54E4.2, CD6/C06B8.7 and CBP1/p300. |
| II. Key autoimmune disease-related pathways and DAF-12/VDR target gene. |
| Pathway |
Representative DAF-12/VDR target genes |
| Autophagy |
TOR/let-363, Beclin1/bec-1, ATG5/Atg5, ULK1/unc-51 |
| Interconnected heterochronic and microRNA genes |
LIN28/lin-28, PER3/lin-42, TRIM71/lin-41, Eif2C2/alg-2, Ago2/alg-1, TIFγ/TRIM33/nhl-2, Ikaros/hbl-1, CSNK1E/Kin-20, lin-14, ain-1 and ain-2. |
| Notch pathway (and Alzheimer's disease) |
CSL /lag-1, NOTCH2/glp-1, lst-2, DUSP7/ lip-1, apl-1, CCT5/cct-5 and SPEN/din-1. |
| RNA interference |
MDA (CADM140)/drh-1, eri-5, and rde-4. |
| SynMuv B/DREAM pathway |
Rbbp48/lin-53, HP1/hpl1, Mi-2β/let-418 and mep-1, lin-13. |
| Sex determination complex |
GLI1/tra-1 and sdc-1. |
| Cellular reprogramming and carcinogenesis |
Rbbp48/lin-53, MDA(CADM140)/drh-1, c-Myc/mml-1, LIN28/lin-28, MDR-1/pgp-9, PGK1/pgk-1, AKT1/akt-1, AKT2/akt-2, RAS/let-60, PDK1/pdk-1,CDK4/cdk-4, CDK5/cdk-5, TNFAIP3/Y50C1A.1, TOR/let-363, Beclin1/bec-1, SMAD4/ daf-3, BRCA1/brc-1 , MTA1/egl-27 and DDX6/cgh-1. |
| Aging/longevity |
Mi-2β/let-418, HSF1/hsf-1, FoxO/daf-16, VDR/daf-12, TOR/let-363, Beclin1/bec-1, SIRT4/Sir-2.4, IGF1R/daf-2, INS/ins-7, Ku80/cku-80 and KRIT1/kri-1, MTA1/egl-27. |
| III. Autoimmune diseases, DAF-12/VDR target genes and well-known auto-antibodies of clinical importance. |
| Type of diseases |
Representative DAF-12/VDRtarget genes |
Representative auto-antibodies ( α- = anti-)
|
| Diabetes mellitus |
HSP90/daf-21, MDA/CADM140/drh-1 |
α-HSP90 andα-MDA/CADM140. |
| Systemic lupus erythematosus |
Ago2/alg-1; Eno1/enol-1, c-Myc/mml-1, La/SSB and /C44E4.4CALR /crt-1, TCP-1/cct-1, NOD2/F28C1.3 |
α-Su/Ago2, α-c-Myc, α-La/SSB, α-TCP-1 and α-NOD2 . |
| Polymyositis and dermatomyositis |
SSB/C44E4.4, U1-RNP/SNRNP70/rnp-7, c-Myc/mml-1, Mi-2β/let-418, TIFβ/TRIM28/ncl-1, TIFα/TRIM24/flt-1, TIFγ/TRIM33/nhl-2, PM/Scl-100/crn-3, Zo/frs-1, PL-12/AARS/ars-1, Ku80/cku-80, MDA (CADM140)/drh-1, SSA/TRIM0/cnb-1, Su/Ago2/alg-1, SM/lsm/Y47G12B.14 ,
PLCL1/pll-1,
BLK/src-1 |
α-Lo/SSB, α-U1-RNP/SNRNP70, α-c-Myc, α- Mi-2β, α-TIFβ/KAP1/TRIM28, α-TIFα/TRIM24/p140, α-TIFγ/TRIM33/p150, α-PM/Scl-100, α-Zo, α-PL-12/AARS, α-Ku80, α-MDA (CADM140), α- Ro-/SSA/TRIM0, α-Su/Ago2, α-SM. |
| Scleroderma |
PM/Scl-100/crn-3, TIFβ/TRIM28/ncl-1, Scl-70/TOP-1, FBN1/Fbl-1, U1-RNP/SNRNP70 /rnp-7, p27/Y39A1A.3 |
α-PM/Scl-100, α-TIFβ/TRIM28, α-PM/Scl-70, α-U1-RNP/SNRNP70. |
| Crohn's disease |
NOD2/F28C1.3 |
α-NOD2. |
| Sjögren's syndrome |
Ro-SSA/cnb-1, p27/Y39A1A.3, CALR /crt-1, |
α-Ro-SSA. |
|
